About Us
About Noxopharm
CEO's Message
Management Team
Board of Directors
Scientific Advisors
Our Network
Pharmorage
ESG Commitment
Technology
Technology Platforms
Chroma™
Sofra™
mRNA Vaccines
Autoimmune Disease
Clinical Trials
Publications
Investor Centre
Share Price
Presentations & Interviews
Annual Reports
Financial Reports
ASX Announcements
Corporate Governance
Investor Fact Sheet
Share Registry Information
Contact Us
Contact Us
Partnering
Working at Noxopharm
ASX Announcements Email Alerts
Investor Centre
Investor Centre
>
ASX Announcements
Share Price
Presentations & Interviews
Annual Reports
Financial Reports
ASX Announcements
Corporate Governance
Investor Fact Sheet
Share Registry Information
ASX Announcements
Filter by Year:
2025
2024
2023
2022
2021
2020
2019
2018
Older
21 Feb 2020
Appendix 2A
21 Feb 2020
FDA grants IND approval to Veyonda
18 Feb 2020
Termination of Convertible Loan
18 Feb 2020
Section 708 Certificate
18 Feb 2020
Appendix 2A
18 Feb 2020
Noxopharm Alliance With GenesisCare
14 Feb 2020
Proposed issue of Securities - NOX
14 Feb 2020
$8.1M Financing & Re-Set of Capital Structure
14 Feb 2020
Pronounced survival benefit in LuPIN interim trial data
12 Feb 2020
Trading Halt
Previous
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
Next
